Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1083 participants.
Also called NCT06153693
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,083 participants
- Sponsor
- Registry
-
NCT06153693
-
- Other papers using this trial's data
- Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Bulgaria, Canada, France, Germany, Italy, Netherlands, Poland, Puerto Rico, Romania, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06153693. Randomized; double masking; primary purpose treatment. Start 2023-11-22 (actual); primary completion 2024-12-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- lorundrostat Dose 1
- Intervention (Drug)
- lorundrostat Dose 2
- Lead sponsor
- Mineralys Therapeutics Inc.
Record details
- Record id
cardio:ct-nct06153693- Content hash
2a0ac53faff92a8d586006a73e9d9f4e8d42b14d5072bc2b881a3103a674b107